Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: A phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period
Kress, Hans Georg, MD, PhD, Orońska, Anna, MD, Kaczmarek, Zbigniew, MD, Kaasa, Stein, MD, PhD, Colberg, Torben, MD, Nolte, Thomas, MD
Published in Clinical therapeutics (01.06.2009)
Published in Clinical therapeutics (01.06.2009)
Get full text
Journal Article